A biotech building a self-injected therapy for a kidney disease, aiming to be a daily pill-like fix for an autoimmune condition.
No revenue; the company is pre-commercial, burning through cash with net losses of USD -0.30B in 2025, funded by investors.
Potential first-in-class drug with Phase IIb data, but no approved product or revenue; competitors like Novartis and Omeros could out-innovate or out-muscle them.
Sell (sector percentile 3) — value F, growth C, profitability D, momentum C-, revisions C-. Updated daily, sector-relative, identical for every user.
Key events, in time order
TD Cowen, Wedbush, and HCW raise targets, reflecting increased attention post-FDA approval
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
